Extension usage examples:
Here's how our browser extension sees the article:
Article summary:
1. This systematic review and meta-analysis of 27 clinical trials with 815 patients found promising clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable esophageal cancer.
2. The pooled rates for pathological complete response (pCR) and major pathological response (MPR) were 31.4% and 48.9%, respectively, while the incidence of treatment-related severe adverse events was 26.9%.
3. Findings suggest the need for randomized clinical trials with long-term follow-up to validate the benefits of immune checkpoint inhibitors.
Article analysis:
The article is a systematic review and meta-analysis of 27 clinical trials with 815 patients that evaluated the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer. The authors conducted a comprehensive search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases to identify relevant original articles and conference proceedings published in English through April 1, 2022. The Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed to extract data from the studies included in the analysis, which were then analyzed using a random-effects model if heterogeneity was significant or a common-effects model otherwise.
The results showed that neoadjuvant immunotherapy had promising clinical outcomes, as evidenced by a pooled pCR rate of 31.4% (95% CI, 27.6%-35.3%) and MPR rate of 48.9% (95% CI, 42%-55%). In terms of safety, the pooled incidence of treatment-related severe adverse events was 26.9% (95% CI 16.7%-38%). Most patients achieved R0 surgical resection (98.6%; 95% CI 97%-99%). Subgroup analyses according to histologic subtype showed that pCR rates were 32.4% (95% CI 28%-37%) in ESCCs and 25.2% (95% CI 16%-35%) in EACs; MPR rate was 49.4% (95% CI 42%-57%) in ESCCs only; while R0 surgical resection rate was 98%-99%.
The article is generally reliable as it provides an up-to-date overview on current evidence regarding neoadjuvant immunotherapy for locally advanced resectable esophageal cancer based on a comprehensive search strategy that included both published literature as well as conference proceedings from reputable sources such as PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases; however there are some potential biases that should be noted when interpreting these findings such as publication bias due to selective reporting or language bias due to only including studies published in English; also missing points such as patient selection criteria or other factors influencing outcomes could have been explored further; additionally more detailed information about each study included would have been beneficial for readers to better understand how each study contributed to the overall results presented here; finally more research is needed to validate these findings through randomized controlled trials with long term follow up before any definitive conclusions can be made about the efficacy or safety of this treatment option for esophageal cancer patients